Iteos Therapeutics Inc Asset Resilience Ratio
Iteos Therapeutics Inc asset resilience ratio. Iteos Therapeutics Inc (ITOS) has an Asset Resilience Ratio of 49.37% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Iteos Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Iteos Therapeutics Inc (2021–2024)
Asset resilience ratio of Iteos Therapeutics Inc from 2021 to 2024. This chart shows how Iteos Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Iteos Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Iteos Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ITOS total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $307.61 Million | 49.37% |
| Total Liquid Assets | $307.61 Million | 49.37% |
Asset Resilience Insights
- Very High Liquidity: Iteos Therapeutics Inc maintains exceptional liquid asset reserves at 49.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Iteos Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Iteos Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Iteos Therapeutics Inc Asset Resilience Ratio by Year (2021–2024)
Iteos Therapeutics Inc asset resilience ratio by year from 2021 to 2024. The table below shows the annual Asset Resilience Ratio data for Iteos Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 51.31% | $352.52 Million | $686.98 Million | +9.26pp |
| 2023-12-31 | 42.05% | $280.74 Million | $667.59 Million | -1.44pp |
| 2022-12-31 | 43.49% | $328.36 Million | $754.99 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $884.71 Million | -- |
About Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more